Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ranitidine
Drug ID BADD_D01913
Description Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries.[A176843] Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818]
Indications and Usage This drug is used alone or with concomitant antacids for the following conditions: short-term treatment of active duodenal ulcer, treating gastric acid hypersecretion due to Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions that may pathologically raise gastric acid levels. It also used in the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose. In addition to the above, ranitidine can be used for the treatment of GERD symptoms, treatment of erosive esophagitis (endoscopically diagnosed) and the maintenance of gastric or duodenal ulcer healing.[L10818,L10821]
Marketing Status approved; withdrawn
ATC Code Not Available
DrugBank ID DB00863
KEGG ID D00422
MeSH ID D011899
PubChem ID 3001055
TTD Drug ID D0B8WN
NDC Product Code 43353-445; 53746-253; 69842-869; 55111-404; 68462-249; 71713-203; 62207-773; 68196-985; 0121-4727; 50268-721; 63868-482; 65162-254; 69842-871; 71335-1327; 0121-0727; 43598-808; 68462-248; 0904-6921; 53746-254; 62207-774; 71335-1621; 11673-849; 27241-109; 30142-505; 45865-416; 63868-480; 65162-664; 67296-1586; 0904-6715; 64679-740; 65162-253; 70000-0033; 55111-131; 64679-741; 27241-110
UNII 884KT10YB7
Synonyms Ranitidine | Ranitidin | N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine | Biotidin | Ranisen | Sostril | Zantac | Zantic | AH-19065 | AH 19065 | AH19065 | Ranitidine Hydrochloride | Hydrochloride, Ranitidine
Chemical Information
Molecular Formula C13H22N4O3S
CAS Registry Number 82530-72-1
SMILES CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Epiglottic cancer22.08.02.009; 16.19.03.0020.000025%Not Available
Gastric cancer stage I16.13.03.005; 07.21.02.0050.000025%Not Available
Gastrointestinal lymphoma16.35.01.006; 07.21.04.014; 01.17.01.0060.000050%Not Available
Hepatic cancer stage I16.07.02.008; 09.04.02.0150.000025%Not Available
Hepatic cancer stage III16.07.02.009; 09.04.02.0160.000025%Not Available
Hepatic cancer stage IV16.07.02.010; 09.04.02.0170.000138%Not Available
Illness08.01.03.091--Not Available
Infant irritability18.04.04.018; 17.02.05.0720.000085%Not Available
Lung carcinoma cell type unspecified stage I22.08.01.026; 16.19.02.0080.000050%Not Available
Lung carcinoma cell type unspecified stage III22.08.01.027; 16.19.02.0090.000025%Not Available
Malignant neoplasm of eye16.34.05.002; 06.12.05.0020.000025%Not Available
Mast cell activation syndrome10.02.01.090; 01.05.01.0300.000025%Not Available
Metastases to oesophagus16.22.02.036; 07.21.03.0110.000025%Not Available
Metastatic lymphoma16.20.01.007; 01.12.01.0070.000025%Not Available
Nasal neoplasm22.08.02.013; 16.19.09.0020.000038%Not Available
Nasal sinus cancer16.19.09.003; 22.08.02.0140.000025%Not Available
Neoplasm of appendix16.13.11.009; 07.21.04.0170.000205%Not Available
Pancreatic carcinoma stage III16.13.10.007; 07.21.09.0120.000025%Not Available
Pancreatic duct dilatation07.18.02.0090.000038%Not Available
Pharyngeal swelling22.04.05.028--Not Available
Precancerous condition08.03.04.0100.000038%Not Available
Prostate cancer stage II21.04.02.014; 16.25.01.0100.000200%Not Available
Prostate cancer stage III21.04.02.015; 16.25.01.0110.000050%Not Available
Prostatic atrophy21.04.01.0110.000025%Not Available
Renal cancer stage II20.01.04.022; 16.08.02.0120.000063%Not Available
Renal cancer stage III20.01.04.023; 16.08.02.0130.000025%Not Available
Splenic neoplasm malignancy unspecified16.21.01.007; 01.13.01.0070.000088%Not Available
Trichoglossia07.14.01.0210.000038%Not Available
Urethral cancer20.07.05.001; 16.08.04.0030.000088%Not Available
Uveal melanoma16.34.04.003; 06.12.04.0030.000025%Not Available
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene